Drugs / pegylated erythropoietin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02950857 | Jun → Sep 2017 | beta thalassemia | Prolong Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegylated erythropoietin | “EPEG (pegylated erythropoietin) - 0.9 µg/kg” NCT02950857 ↗ |
| Known as | EPEG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02950857 ↗ |
| Route | Subcutaneous | “Four weekly subcutaneous injections of 0.9 µg/kg EPEG” NCT02950857 ↗ |